Observing patients with embolic stroke of undetermined source
Registry Study for the Observation of Patients With ESUS/Cryptogenic Stroke (ESUS = Embolic Stroke of Undetermined Source)
This study is tracking adults with unexplained strokes to see if using a heart monitor can help find the cause and improve their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 750 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ludwig-Maximilians - University of Munich Academic / other |
| Locations | 1 site (Munich) |
| Trial ID | NCT03820375 on ClinicalTrials.gov |
What this trial studies
This observational registry study aims to follow adult patients with embolic stroke of undetermined source (ESUS) for 36 months to establish a structured diagnostic and therapeutic pathway. Patients aged 18 and older will be included and monitored, with treatment algorithms tailored based on age and clinical findings. An insertable cardiac monitor will be implanted in all participants to aid in the detection of potential cardiac sources of stroke. The study seeks to gather data that could lead to individualized treatment approaches for ESUS patients.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have experienced an embolic stroke of undetermined source.
Not a fit: Patients with known causes of stroke or those who do not meet the inclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and treatment strategies for patients suffering from ESUS.
How similar studies have performed: While there is ongoing research in this area, this specific approach is novel and aims to fill a gap in the current understanding of ESUS management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Embolic stroke of undetermined source or cryptogenic stroke; defined as: non-lacunar brain infarction without proximal arterial stenosis or cardioembolic source or other etiology (e.g. vasculitis, cervical artery dissection) * ≥18 years * written consent to participation in the study register by the patient or the legal guardian or authorised representative at the time of inclusion in the study
Where this trial is running
Munich
- Ludwig Maximilians University — Munich, Germany (Recruiting)
Study contacts
- Principal investigator: Lars Kellert — Ludwig-Maximilians - University of Munich
- Study coordinator: Lars Kellert, MD
- Email: Lars.Kellert@med.uni-muenchen.de
- Phone: 0049 (0) 89 4400 73962
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.